Top
image credit: Adobe Stock

Freeline cuts more jobs and halts Fabry gene therapy work

April 4, 2023

Freeline’s retrenchment adds to the growing list of reorganizations, job cuts and other strategic maneuvers young drugmakers have pursued amid a sharp downturn in the public markets.

Already this year, at least 56 biotech companies have announced layoffs, according to a BioPharma Dive tally. More than ten of those companies are gene and cell therapy developers, which were hit particularly hard early on in the sector’s pullback.

Read More on Biopharma Dive